AMAM Key Statistics, Chart & Performance
The current stock price of AMAM is 28 USD. In the past month the price increased by 0.79%. In the past year, price increased by 188.96%.
AMAM Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to AMAM. When comparing the yearly performance of all stocks, AMAM is one of the better performing stocks in the market, outperforming 98.51% of all stocks.
AMAM Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to AMAM. While AMAM has a great health rating, there are worries on its profitability.
AMAM Financial Highlights
Over the last trailing twelve months AMAM reported a non-GAAP Earnings per Share(EPS) of -0.57. The EPS decreased by -16% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -30.43% | ||
| ROE | -34.09% | ||
| Debt/Equity | 0 |
AMAM Forecast & Estimates
14 analysts have analysed AMAM and the average price target is 29.07 USD. This implies a price increase of 3.82% is expected in the next year compared to the current price of 28.
For the next year, analysts expect an EPS growth of -159.66% and a revenue growth -57.14% for AMAM
AMAM Ownership
About AMAM
Company Profile
Ambrx Biopharma Inc is a US-based company operating in Biotechnology industry. The company is headquartered in La Jolla, California and currently employs 66 full-time employees. The company went IPO on 2021-06-18. Ambrx Biopharma Inc. is a clinical-stage biopharmaceutical company. The firm is focused on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. The company is advancing a focused portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its ADC targeting Human epidermal growth factor receptor 2 (HER2). The company uses genetic code technology platform to discover and develop engineered precision biologics. Its genetic code technology platform allows to incorporate, in a site-specific manner, synthetic amino acids (SAA), into proteins within living cells. Its SAA incorporation technology is designed to develop a range of product candidate modality, such as modified cytokines and bispecific antibodies, and others.
Company Info
NEW AMBRX BIOPHARMA INC
10975 North Torrey Pines Road
La Jolla CALIFORNIA US
CEO: Feng Tian
Employees: 66
Phone: 18588752400
NEW AMBRX BIOPHARMA INC / AMAM FAQ
What does NEW AMBRX BIOPHARMA INC do?
Ambrx Biopharma Inc is a US-based company operating in Biotechnology industry. The company is headquartered in La Jolla, California and currently employs 66 full-time employees. The company went IPO on 2021-06-18. Ambrx Biopharma Inc. is a clinical-stage biopharmaceutical company. The firm is focused on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. The company is advancing a focused portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its ADC targeting Human epidermal growth factor receptor 2 (HER2). The company uses genetic code technology platform to discover and develop engineered precision biologics. Its genetic code technology platform allows to incorporate, in a site-specific manner, synthetic amino acids (SAA), into proteins within living cells. Its SAA incorporation technology is designed to develop a range of product candidate modality, such as modified cytokines and bispecific antibodies, and others.
Can you provide the latest stock price for NEW AMBRX BIOPHARMA INC?
The current stock price of AMAM is 28 USD. The price increased by 0.07% in the last trading session.
What is the dividend status of NEW AMBRX BIOPHARMA INC?
AMAM does not pay a dividend.
How is the ChartMill rating for NEW AMBRX BIOPHARMA INC?
AMAM has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the expected growth for AMAM stock?
The Revenue of NEW AMBRX BIOPHARMA INC (AMAM) is expected to decline by -57.14% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the market capitalization of AMAM stock?
NEW AMBRX BIOPHARMA INC (AMAM) has a market capitalization of 12.42B USD. This makes AMAM a Large Cap stock.
Who owns NEW AMBRX BIOPHARMA INC?
You can find the ownership structure of NEW AMBRX BIOPHARMA INC (AMAM) on the Ownership tab.